Health‐related consequences of overactive bladder: an economic perspective

About 34 million people in the USA have an overactive bladder (OAB), a condition characterized by urinary urgency, with or without urinary incontinence, and usually frequency and nocturia. This condition is associated with increased health risks (e.g. urinary tract infection, falls and fall‐related injuries, including broken bones), as well as admission to nursing homes and prolonged hospital stays. The annual costs associated with OAB in the community setting are >$9 billion, including $2.9 billion for diagnosis and treatment, $1.5 billion for routine care, $3.9 billion for treatment of health‐related consequences, and $841 million in lost productivity. These cost patterns raise the possibility that treating OAB at an early stage may both improve patient care and minimize overall use of healthcare resources. However, before a thorough economic analysis of OAB can be undertaken, more data are needed about the long‐term costs and the pathogenesis of OAB‐related conditions.